We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
Elekta will publish its interim report for May-October 2013/14 on December 4, as per: · The report will be published at 07:30 CET. · Elekta will host a telephone conference at 10:00-11:00 CET with Tomas Puusepp, President and CEO and Håkan Bergström, CFO.
To take part in the conference call, please dial in about five minutes in advance,
use the telephone numbers below and the access code 938863.
• UK dial-in number: +44 (0)20 7162 0077
• US dial-in number: + 1 877 491 0064
• Swedish dial-in number: +46 (0)8 5052 0110
The telephone conference will be broadcast live online (for the possibility to ask questions, please also dial in). Please use the link:
# # #
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO: EKTAB. Website: www.elekta.com.